273 related articles for article (PubMed ID: 20869467)
21. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
[TBL] [Abstract][Full Text] [Related]
22. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study.
Juurlink DN; Stukel TA; Kwong J; Kopp A; McGeer A; Upshur RE; Manuel DG; Moineddin R; Wilson K
Arch Intern Med; 2006 Nov; 166(20):2217-21. PubMed ID: 17101939
[TBL] [Abstract][Full Text] [Related]
23. Lack of association of Guillain-Barré syndrome with vaccinations.
Baxter R; Bakshi N; Fireman B; Lewis E; Ray P; Vellozzi C; Klein NP
Clin Infect Dis; 2013 Jul; 57(2):197-204. PubMed ID: 23580737
[TBL] [Abstract][Full Text] [Related]
24. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.
Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K
Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652
[TBL] [Abstract][Full Text] [Related]
25. Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition.
Choe YJ; Cho H; Bae GR; Lee JK
Vaccine; 2011 Mar; 29(11):2066-70. PubMed ID: 21255684
[TBL] [Abstract][Full Text] [Related]
26. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.
Choe YJ; Cho H; Kim SN; Bae GR; Lee JK
Vaccine; 2011 Oct; 29(44):7727-32. PubMed ID: 21827815
[TBL] [Abstract][Full Text] [Related]
27. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
[TBL] [Abstract][Full Text] [Related]
28. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
[TBL] [Abstract][Full Text] [Related]
29. Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season.
Perez-Vilar S; Wernecke M; Arya D; Lo AC; Lufkin B; Hu M; Chu S; MaCurdy TE; Kelman J; Forshee RA
Vaccine; 2019 Jun; 37(29):3856-3865. PubMed ID: 31122853
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System.
Borja-Hart NL; Benavides S; Christensen C
Ann Pharmacother; 2009 Feb; 43(2):356-9. PubMed ID: 19155346
[TBL] [Abstract][Full Text] [Related]
31. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination.
Velentgas P; Amato AA; Bohn RL; Chan KA; Cochrane T; Funch DP; Dashevsky I; Duddy AL; Gladowski P; Greenberg SA; Kramer JM; McMahill-Walraven C; Nakasato C; Spettell CM; Syat BL; Wahl PM; Walker AM; Zhang F; Brown JS; Platt R
Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1350-8. PubMed ID: 22807266
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000 and 2001.
Burwen DR; Ball R; Bryan WW; Izurieta HS; La Voie L; Gibbs NA; Kliman R; Braun MM
Am J Prev Med; 2010 Oct; 39(4):296-304. PubMed ID: 20837279
[TBL] [Abstract][Full Text] [Related]
33. Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5-14 years old children.
Esteghamati A; Gouya MM; Keshtkar AA; Mahoney F
Vaccine; 2008 Sep; 26(39):5058-61. PubMed ID: 18662736
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
[TBL] [Abstract][Full Text] [Related]
35. Recurrent Guillain-Barre syndrome following vaccination.
Baxter R; Lewis N; Bakshi N; Vellozzi C; Klein NP;
Clin Infect Dis; 2012 Mar; 54(6):800-4. PubMed ID: 22267712
[TBL] [Abstract][Full Text] [Related]
36. Influenza vaccination and Guillain Barre syndrome.
Geier MR; Geier DA; Zahalsky AC
Clin Immunol; 2003 May; 107(2):116-21. PubMed ID: 12763480
[TBL] [Abstract][Full Text] [Related]
37. Atypical forms of Guillain-Barré syndrome and H1N1-influenza vaccination.
Shaikh AG; Termsarasab P; Nwankwo C; Rao-Frisch A; Katirji B
Vaccine; 2012 May; 30(22):3251-4. PubMed ID: 22429755
[TBL] [Abstract][Full Text] [Related]
38. Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination.
Patja A; Paunio M; Kinnunen E; Junttila O; Hovi T; Peltola H
J Pediatr; 2001 Feb; 138(2):250-4. PubMed ID: 11174624
[TBL] [Abstract][Full Text] [Related]
39. Relationship between Guillain-Barré syndrome, influenza-related hospitalizations, and influenza vaccine coverage.
Iqbal S; Li R; Gargiullo P; Vellozzi C
Vaccine; 2015 Apr; 33(17):2045-9. PubMed ID: 25749247
[TBL] [Abstract][Full Text] [Related]
40. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink.
Yih WK; Nordin JD; Kulldorff M; Lewis E; Lieu TA; Shi P; Weintraub ES
Vaccine; 2009 Jul; 27(32):4257-62. PubMed ID: 19486957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
